Table 2 Documented obesity-related comorbidities, referral to dietician or endocrine evaluation according to prescription of anti-obesity medications (AOMs).

From: Real -world experience with anti-obesity medications treatment in children and adolescents with overweight and obesity in Israel

 

Patients with prescription (≥1) of AOMs at age < 18 years

Patients without prescription AOMs at age < 18 years

P1

n

Males

913

16,2351

 

Females

1 323

14,2621

 

Dyslipidemia

males

93 (10.2%)

2274 (1.4%)

<0.001

females

138 (10.4%)

2347 (1.6%)

<0.001

P2

0.852

<0.001

 

Type 2 diabetes

males

54 (5.9%)

56 (0.03%)

<0.001

females

78 (5.9%)

83 (0.06%)

<0.001

P2

0.985

0.002

 

IGT

males

101 (11.1%)

841 (0.5%)

<0.001

females

126 (9.5%)

934 (0.7%)

<0.001

P2

0.236

<0.001

 

Hypertension

males

94 (10.3%)

1885 (1.2%)

<0.001

females

90 (6.8%)

939 (0.7%)

<0.001

P2

0.003

 < 0.001

 

OSA

males

19 (2.1%)

209 (0.1%)

<0.001

females

19 (1.4%)

197 (0.1%)

<0.001

P2

0.246

0.478

 

NAFLD

males

263 (28.8%)

2926 (1.8%)

<0.001

females

311 (23.5%)

2109 (1.5%)

<0.001

P2

0.005

<0.001

 

PTC

males

16 (1.8%)

149 (0.1%)

<0.001

females

34 (2.6%)

484 (0.3%)

<0.001

P2

0.199

<0.001

 

PCO

females

21 (1.6%)

100 (0.1%)

<0.001

Referral to dietician

males

647 (70.9%)

25,127 (15.5%)

<0.001

females

994 (75.1%)

35,003 (24.5%)

<0.001

P2

0.025

<0.001

 

Referral to endocrine evaluation

males

510 (55.9%)

11,190 (6.9%)

<0.001

females

778 (58.8%)

13,323 (9.3%)

<0.001

P2

0.166

<0.001

 
  1. Data is presented as n (%). P1 represent comparison between groups using Pearsons’ chi square tests. P2 represent comparison between sexes using Pearsons’ chi square tests.
  2. IGT impaired glucose tolerance, OSA obstructive sleep apnea, NAFLD non-alcoholic fatty liver disease, PTC pseudotumor cerebri, PCO polycystic ovary.
Back to article page